Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
Zhi-cheng JingYue-Jin Yang

Abstract

Bosentan has an established role in the management of pulmonary arterial hypertension (PAH). This clinical trial assessed the benefits of bosentan in the Chinese population. We investigated the efficacy and safety of bosentan in 92 Chinese citizens (mean +/- standard deviation age, 29.0 +/- 3.8 years) with PAH for a minimum of 12 weeks. All received bosentan (62.5 mg twice daily) for 4 weeks; then, patients who weighed <40 kg received 62.5 mg bosentan twice daily and patients who weighed >40 kg received 125 mg twice daily. All patients were eligible to continue bosentan beyond 12 weeks. The primary end point was a change in exercise capacity from baseline to 12 and 24 weeks. Secondary end points included a change in World Health Organization (WHO) functional class and changes in cardiopulmonary hemodynamics. At baseline, 66 patients (72%) were in WHO functional class III; presentation was 37 (40%) with idiopathic PAH (iPAH), 34 (37%) with PAH related to congenital heart disease (CHD), and 21 (23%) with PAH related to connective tissue disease (CTD). Exercise capacity increased to 67.8 m after 12 weeks and 92.6 m after 24 weeks (p < 0.001). After 24 weeks, WHO functional class decreased (-0.8 +/- 0.6; p < 0.001), mean pulmonary ...Continue Reading

References

Apr 1, 1986·Arthritis and Rheumatism·A M StupiT A Medsger
Jun 15, 2004·Journal of the American College of Cardiology·Robyn J BarstSean Gaine
Jan 12, 2005·The American Journal of Cardiology·Steven M KawutRobyn J Barst
Jan 29, 2005·International Journal of Cardiology·Michael A GatzoulisJ Simon R Gibbs
Feb 3, 2005·The European Respiratory Journal·V V McLaughlinL J Rubin
Jan 25, 2006·European Heart Journal·Steeve ProvencherGérald Simonneau
Jun 28, 2006·Circulation·Nazzareno GalièUNKNOWN Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators
Apr 17, 2007·International Journal of Cardiology·Melinda CarringtonSimon Stewart
Jul 31, 2007·International Journal of Cardiology·Michael A GatzoulisUNKNOWN BREATHE-5 Investigators
Dec 20, 2007·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Mugdha ThakurDavid B Matchar
Oct 30, 2008·The Annals of Pharmacotherapy·Sandra L Hrometz, Kelly M Shields

❮ Previous
Next ❯

Citations

Dec 12, 2012·American Journal of Respiratory and Critical Care Medicine·Wen-Hui WuZhi-Cheng Jing
Dec 23, 2010·Future Cardiology·Nathan Dwyer, David Kilpatrick
Jun 16, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Geoff StrangeEli Gabbay
Feb 2, 2010·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Myung H Park, Lewis J Rubin
Sep 20, 2015·American Heart Journal·Kishan S ParikhZainab Samad
Jan 5, 2014·Internal Medicine Journal·G StrangeA Keogh
Apr 8, 2016·Cardiology in Review·Cristel S HjortshøjLars Søndergaard
Jun 2, 2018·Basic & Clinical Pharmacology & Toxicology·Jonas PedersenDaniela Grimm
Apr 16, 2021·Expert Review of Cardiovascular Therapy·Ana Barradas-PiresKonstantinos Dimopoulos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
Jagdish HiremathTRUST Study Group
Journal of Postgraduate Medicine
U M Thatte, S B Bavdekar
Proceedings of the American Thoracic Society
Scott D HalpernSteven M Kawut
Proceedings of the American Thoracic Society
Mardi Gomberg-Maitland
© 2021 Meta ULC. All rights reserved